Alterity Therapeutics (ATHE) issued a letter to shareholders from CEO David Stamler, stating in part: “As we again begin a new year, I am filled with optimism for 2025 and what lies ahead for Alterity ...

Background Multiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as combination of parkinsonism, cerebellar syndrome and dysautonomia. Disease ...

In a letter addressed to President Joan Gabel and Senior Vice President Myron Frans, MSA demands that Clark immediately resign and an interim chief who is “committed to diversity and inclusion, ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that ... A routine blood test that measures a patient's inflammation levels could ...

Background Global hippocampal atrophy is a hallmark of Alzheimer’s dementia and has been similarly reported in Parkinson’s disease dementia (PDD ... from the SingHealth Foundation and the National ...

Background: External anal sphincter (EAS) electromyography (EMG) abnormalities can distinguish multiple system atrophy (MSA) from Parkinson’s disease in the first five years after disease onset.

but remains in development for MSA; and Novartis and UCB's oral candidate minzasolmin, which is in phase 2. AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy ...

MSA is a rare condition that is commonly mistaken for Parkinson's disease. The cause of MSA is unknown but does not appear to be genetic. What scientists have found is that certain parts of the brain ...

Jan. 2, 2025 — Patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease (CVD) compared to those with ...

In both the GATHER 1 and 2 trials, avacincaptad pegol given as an injection into the eye slowed disease progression ... remain committed to serving unmet patient needs globally," she added.